[Prognostic value of neurohormones in heart failure in clinical practice].
The decisive therapeutic advances achieved in cardiac insufficiency in recent years have been thanks to drugs affecting the different neurohormonal systems in operation. Neurohormonal activation plays a major role in cardiac insufficiency. Several neuro-endocrine mechanisms exert vasoconstrictor effects: the sympathetic system, the renin-angiotensin-aldosterone system and the endothelins. In cardiac insufficiency these effects are counterbalanced, but insufficiently, by vasodilatory agents, mainly the natiuretic peptides, EDRF (endothelium derived relaxing factor), vasodilatory prostaglandins, bradykinin and adrenomedulin. Neurohormonal activation is an excellent marker of not only the severity but also the prognosis of cardiac insufficiency. Standardisation of dosage is desirable in order to allow the use of neurohormonal drugs in a very large number of centres.
Pousset
F
F
Hôpital La Pitié-La Salpêtrière, Paris.
Isnard
R
R
Komajda
M
M
D015415:Biomarkers / Q000032:analysis*; D001920:Bradykinin / Q000032:analysis / Q000494:pharmacology; D002303:Cardiac Output, Low; D006801:Humans; D045283:Natriuretic Agents / Q000032:analysis / Q000494:pharmacology; D009569:Nitric Oxide / Q000032:analysis / Q000494:pharmacology; D011237:Predictive Value of Tests; D011379:Prognosis; D011453:Prostaglandins / Q000032:analysis / Q000494:pharmacology; D012084:Renin-Angiotensin System / Q000502:physiology*; D012720:Severity of Illness Index
D015415:Biomarkers; D045283:Natriuretic Agents; D011453:Prostaglandins; D009569:Nitric Oxide; D001920:Bradykinin
Valeur pronostique des neuro-hormones dans l'insuffisance cardiaque en pratique clinique.